Digitate Partners with Toshiba Global Commerce Solutions to Deliver Next Generation, Intelligence-enabled Connected Services
19.9.2023 07:00:00 EEST | Business Wire | Press release
Digitate, a leading provider of SaaS-based enterprise software for IT and business operations, today announced a strategic partnership with Toshiba Global Commerce Solutions (Toshiba), the global market share leader in installed electronic point of sale technology, to deliver next-generation store support service to retailers throughout Europe leveraging Digitate’s ignio™ AIOps platform.
The partnership will provide Toshiba Global Commerce Solutions customers access to AI-driven, class-leading support across a full multi-vendor retail store environment. It will also ensure resilient operations for the customers’ critical business functions by automatically flagging and diagnosing problems, proactively resolving them, in addition to helping predict and prevent them.
“Digitate’s strategic partnership with Toshiba Global Commerce Solutions delivers the technology backbone for its Connected Services offering, transforming their Command Center operations and enhancing service delivery for its retail customers,” said Ritu Dubey, Global Head of New Business Sales and Market Development, at Digitate. “We are dedicated to bringing together the best-in-class solutions, powered by ignio™, to accelerate customers’ autonomous retail enterprise journeys while helping Toshiba Global Commerce Solutions build a solid foundation for future innovation and growth.”
In April 2023, Digitate deployed ignio™ at Toshiba Global Commerce Solutions in just 21 days – a record speed for an ignio™ deployment, demonstrating the time to value Toshiba Global Commerce Solutions’ customers throughout Europe can expect when choosing their intelligent Connected Services.
"Through our partnership with Digitate, we have been able to make a step-change to the capability of the services we can offer to our customers. The ignio™ AIOps technologies enable us to continuously innovate in a competitive store services market,” said Margriet van Schaik, VP of Services at Toshiba Global Commerce Solutions in Europe. “Expanding the Connected Services offering to recognize the complexity of retail stores and the technologies retailers deploy beyond Toshiba’s own, moves the retailer maintenance model from reactive to an AI-enabled predictive model. And helping retailers delight their customers is something they are asking for every day.”
Additionally, Jules Harms, Director of Professional Services at Toshiba Global Commerce Solutions in Europe, added, “By gathering insights from devices and software applications, then using ignio™ AI-enabled analytics to understand component and software process failure patterns, retailers can proactively fix issues before they disrupt retail store operations. And the knock-on effect of reducing carbon emissions through fewer physical engineer visits to stores is only good news for the planet, and environmentally conscious retailers and consumers.”
About Toshiba Global Commerce Solutions
Toshiba Global Commerce Solutions empowers retail to thrive and prosper through a dynamic ecosystem of smarter, more agile solutions and services that enable retailers to resiliently evolve with generations of consumers and adapt to market conditions. Supported by a global organization of devoted employees and partners, retailers gain more visibility and control over operations, while enjoying the flexibility to build, scale, and transform retail experiences that anticipate and fulfill consumers’ ever-changing needs. Visit commerce.toshiba.com and engage with us on X, formerly known as Twitter, LinkedIn, Instagram, Facebook, and YouTube, to learn more.
About Digitate
Digitate is a leading software provider bringing agility, assurance, and resiliency to IT and business operations. Digitate’s flagship product, ignio™, is an award-winning AIOps solution that reimagines the enterprise business landscape with its distinctive closed-loop approach. It combines context, insights, and intelligent automation to resolve and prevent issues autonomously. Our customers span multiple industries and include global enterprises that are leaders and innovators. To stay up to date on ignio™ news and learn how our clients across the globe have benefited from our innovative solutions, visit us at www.digitate.com and follow Digitate on X and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230918426111/en/
Contact information
Roy Heuwer
digitate@progresscommunications.eu
Progress Communications for Digitate
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 12:00:00 EEST | Press release
The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that elevates high-performance riders and horses to their rightful place on the world stage. Built on merit, integrity, and excellence, the PJL brings together the world’s best athletes to compete for the biggest prize pot in the discipline’s history, helping to create a more resilient, long-term financial model for the sport. Represented by sixteen teams, the PJL will introduce an industry-first rider selection process from a pool of 250 of the world’s leading riders. World-class, immersive events will unfold across fourteen ic
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 12:00:00 EEST | Press release
Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkbj) for the treatment of spastic cerebral palsy (CP). On top of safety and tolerability, the study will evaluate improvements in daily functioning, quality of life, motor abilities, and neurodevelopmental measures of the Cenegermin-bkbj intranasal formulation. CP is the most common motor disability in childhood, caused by injury or changes during early brain development. The most prevalent form, spastic CP, leads to muscle stiffness and difficulty with movement.2 “Cerebral palsy is a devastating disease, and for patients and families there are still no proven treatments beyond supportive care,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “With our emerging intranasal NGF p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom